Attachment

From: "Collins, Francis (NIH/OD) [E]" </O=NIH/OU=EXCHANGE ADMINISTRATIVE GROUP (FY DIBOHF23SPDLT)/CN=RECIPIENTS/CN=COLLINSFR> To: 'Qi fda.hhs.gov" fe fda.hhs.gov> Ce: "Eiss, Robert (NIH/FIC) [E]" <{{f@mail.nih.gov>, "Glass, Roger (NIH/FIC) [E]" HBB omail nih.gov>, "Wolinetz, Carrie (NIH/OD) [E]" EEE ih 20v>, "Tabak, Lawrence (NIH/OD) [E]" <M nih. gov>, "Baker, Rebecca (NIH/OD) [E]" <@ 0d.nih.gov> Subject: Upcoming meeting with Gates Foundation and NIH Date: Fri, 19 May 2017 18:22:14 -0400 Importance: Normal Attachments: DRAFT_agenda_BMGF-NIH_ meeting 2017_5_12 (003).docx Dear Scott, Over the past several years, the scientific leadership of the NIH and Bill & Melinda Gates Foundation has met annually to review progress of joint activities and plan future projects. Bill Gates will personally join our next workshop, to take place Friday, June 2, at the John Porter Neuroscience Research Center on the NIH campus, beginning at 8:30 AM __| will co-chair the meeting with Dr. Trevor Mundel, President of the Global Health Division at the Bill & Melinda Gates Foundation. Though I am sure your schedule is packed, we'd be delighted if you could join part or all of the morning session, given the relevance of the topics. Discussion will include: e State-of- the-art developments in global health vaccine R&D , with emphasis on therapeutic vaccines and structure-based immunogen design; e New concepts in cell-phone enabled point-of-care diagnostics, including development of open interface standards, and e Strategies to create a durable network of African sites capable of licensure for standard trials, among other clinical and translational research capacity needs to be addressed by a new partnership called the Coalition for African Research and Innovation. We are finalizing an agenda, which I will share once available, with logistical details. In the interim, I attach the current draft agenda. We have engaged several FDA colleagues in developing the panel session on POC diagnostics, including Alberto Gutierrez. I hope you can make it. Your perspectives would be of great value, and the discussion will give you a close sense of some of the global health product development priorities and pathways pursued jointly by NIH and the Gates Foundation. Best regards, Francis